{"abstract": "The Deal Professor examines the state of play in Novartis\u2018s effort to squeeze out minority shareholders of Alcon now that it controls the eye care company.", "web_url": "https://dealbook.nytimes.com/2010/10/26/the-endgame-for-alcon-and-novartis/", "snippet": "The Deal Professor examines the state of play in Novartis\u2018s effort to squeeze out minority shareholders of Alcon now that it controls the eye care company.", "lead_paragraph": "10:54 a.m. | Updated It is very likely that we are heading into the endgame in Novartis\u2019s attempt to acquire the remaining 23 percent of the eye care company Alcon that Novartis, the big Swiss drug maker, does not already own. The tea leaves support such a conclusion.", "source": "The New York Times", "multimedia": [], "headline": {"main": "The Endgame for Alcon and Novartis", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Alcon Incorporated", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Novartis AG", "rank": 3, "major": "N"}], "pub_date": "2010-10-26T19:47:35+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Steven Davidoff Solomon", "person": [{"firstname": "Steven", "middlename": "Davidoff", "lastname": "Solomon", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/f3b66062-fddf-55e2-afc1-f8940f7d9e56", "word_count": 857, "uri": "nyt://article/f3b66062-fddf-55e2-afc1-f8940f7d9e56"}